This week, we aim for an INFINITe allograft lifespan. or flozination in kidney transplant.
This week, we will discuss the POTCAST trial. It is a cardiology trial - but potassium belongs to nephrology.
This week, we will discuss the VALIANT study, pegcetacoplan in C3G and IC MPGN.
2025 was rich in successful stories. Here are the top 10 that impressed our audience.
SGLT2i have reshaped cardiorenal care, but kidney transplant recipients have mostly been left out of the story. INFINITI starts to close that gap, testing the safety and physiology of dapagliflozin in stable KTR.
Do #flozins behave the same in transplanted kidneys? Check out the VA by Janany Sabescumar
Los iSGLT2 han revolucionado la protección cardiorrenal, pero los trasplantados renales han quedado fuera de la historia. El ensayo INFINITI empieza a cerrar esa brecha. ¿Flozinaran igual los iSGLT2 en el riñón trasplantado? Revisa el resumen visual creado por Janany Sabescumar
NephJC continues to host its live journal clubs and real-time discussions on Bluesky where open dialogue, shared learning, and critical appraisal are central to what we do. For now, our scheduled chats and discussions will continue on Bluesky.
We are also expanding our presence on Instagram with a complementary goal. Instagram allows us to connect with nephrologists and the public who may not be active on X or Bluesky but who are still interested in practice-relevant research, methodology, and staying informed on ongoing NephJC activities. For many clinicians, Instagram serves as an accessible entry point rather than a space for in-depth discussion.
The NephJC editorial team recognizes that Instagram does not allow for the same type of open, back-and-forth dialogue that defines our journal clubs. We are not aiming to replicate that experience there. Instead, we see Instagram as a way to highlight important studies, share key concepts, and guide interested readers toward platforms where deeper discussion and engagement are possible.
Our commitment to thoughtful, inclusive, and rigorous discussion remains the same. Instagram is simply another way to welcome more colleagues into the NephJC community.
¿Elevar el K⁺ al rango alto-normal puede reducir las descargas del DAI y las hospitalizaciones? POTCAST desafía nuestro miedo al potasio.
Revisa el resumen visual por Jeyakumar Meyyappan y únete a la conversación en #NephJC
Can pushing K⁺ to the high-normal range reduce ICD shocks and hospitalizations? POTCAST challenges our fear of potassium.
Check out the VA by Jeyakumar Meyyappan and join the #NephJC conversation
Check out VALIANT recap: a 26-week analysis of the phase 3 trial of pegcetacoplan in C3GN! Thread by NephJC intern Bogdan Agavriloaei.
1/10 Last #NephJC we discussed pegcetacoplan in C3 glomerulopathy and Immune-Complex MPGN #TenPostNephJC
— Nephrology Journal Club (@NephJC) January 16, 2026
Given the central role of complement dysregulation in C3GN, the 🔑 question was whether 🎯 complement inhibition could deliver clinical benefithttps://t.co/1GyC3P8emi pic.twitter.com/Hllq7tEJaG
El ensayo clínico aleatorizado fase 3 VALIANT demostró que la inhibición proximal de C3 con pegcetacoplan logra una reducción significativamente mayor de la proteinuria en comparación con placebo en pacientes con glomerulopatía C3 (C3G) y glomerulonefritis membranoproliferativa primaria mediada por complejos inmunes (IC-MPGN). Este estudio se basa en estrategias previas de inhibición proximal del complemento y refuerza el papel de las terapias dirigidas a la fisiopatología en la C3G.
No te pierdas el resumen visual creado por Dra. Akshaya Jayachandran y súmate a la discusión en #NephJC por Bluesky 🦋
The VALIANT phase 3 RCT shows that proximal C3 inhibition with pegcetacoplan leads to a significantly greater reduction in proteinuria compared with placebo in patients with C3G and primary immune-complex MPGN. This trial builds on prior upstream complement strategies and strengthens the case for disease-targeted therapy in C3G.
Check out the VA Dr. Akshaya Jayachandran and don´t forget to join #NephJC on bluesky.
En pacientes con lesión renal aguda en diálisis, se evaluó si una estrategia más conservadora impacta en la recuperación renal. ¿Será que menos es más? Únete a la discusión del ensayo clínico LIBERATE-D y, antes, no olvides revisar el resumen visual creado por Sejal Lakhani
In patients with dialysis-dependent acute kidney injury, a conservative dialysis strategy was evaluated in the LIBERATE-D trial. Could less be more? Join the discussion in #NephJC, but first, check out the VA created by Sejal Lakhani
Check out PISCES recap: a whale of a tale of fish oil and cardio-protection in ESRD! Thread by NephJC intern Sai Vani
